# Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)

> **NCT01279707** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Queen Mary University of London** · enrollment: 55 (estimated)

## Conditions studied

- Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia

## Interventions

- **BIOLOGICAL:** humanised monoclonal antibody, veltuzumab
- **BIOLOGICAL:** humanised monoclonal antibody epratuzumab
- **BIOLOGICAL:** humanised monoclonal antibodies veltuzumab and epratuzumab

## Key facts

- **NCT ID:** NCT01279707
- **Lead sponsor:** Queen Mary University of London
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-01
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2014-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01279707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01279707, "Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01279707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*